Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3019% above fair value
$1.34−0.26 (-16.51%)
Close on Nov 12, 2026Market cap $160.56MP/E –Yield –
Fate Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Fate Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -2760.0%. For fiscal 2025 it was -2222.4%, against -1542.6% the year before. The highest annual figure on record is -299.9% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2222.4% | −679.8 |
| FY2024 | Dec 31, 2024 | -1542.6% | −1242.8 |
| FY2023 | Dec 31, 2023 | -299.9% | +20.4 |
| FY2022 | Dec 31, 2022 | -320.2% | +68.3 |
| FY2021 | Dec 31, 2021 | -388.6% | +18.9 |
| FY2020 | Dec 31, 2020 | -407.5% | +535.7 |
| FY2019 | Dec 31, 2019 | -943.1% | +472.3 |
| FY2018 | Dec 31, 2018 | -1415.4% | −389.5 |
| FY2017 | Dec 31, 2017 | -1025.9% | −299.8 |
| FY2016 | Dec 31, 2016 | -726.1% | +416.7 |
| FY2015 | Dec 31, 2015 | -1142.8% | +677.5 |
| FY2013 | Dec 31, 2013 | -1820.3% | −1312.5 |
| FY2012 | Dec 31, 2012 | -507.8% | +628.4 |
| FY2011 | Dec 31, 2011 | -1136.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1495.4% | +443.2 |
| Q1 FY2026 | Mar 31, 2026 | -2540.4% | −6.3 |
| Q4 FY2025 | Dec 31, 2025 | -2536.2% | +783.6 |
| Q3 FY2025 | Sep 30, 2025 | -1995.1% | −291.2 |
| Q2 FY2025 | Jun 30, 2025 | -1938.5% | −1272.8 |
| Q1 FY2025 | Mar 31, 2025 | -2534.1% | +118.8 |
| Q4 FY2024 | Dec 31, 2024 | -3319.8% | −451.3 |
| Q3 FY2024 | Sep 30, 2024 | -1703.9% | +933.9 |
| Q2 FY2024 | Jun 30, 2024 | -665.7% | +6040.1 |
| Q1 FY2024 | Mar 31, 2024 | -2652.9% | −2604.4 |
| Q4 FY2023 | Dec 31, 2023 | -2868.4% | −2723.2 |
| Q3 FY2023 | Sep 30, 2023 | -2637.8% | −2061.1 |
| Q2 FY2023 | Jun 30, 2023 | -6705.8% | −6257.7 |
| Q1 FY2023 | Mar 31, 2023 | -48.5% | +355.9 |
| Q4 FY2022 | Dec 31, 2022 | -145.2% | +261.2 |
| Q3 FY2022 | Sep 30, 2022 | -576.7% | −192.7 |
| Q2 FY2022 | Jun 30, 2022 | -448.1% | −99.3 |
| Q1 FY2022 | Mar 31, 2022 | -404.4% | +10.3 |
| Q4 FY2021 | Dec 31, 2021 | -406.5% | −196.4 |
| Q3 FY2021 | Sep 30, 2021 | -384.0% | +32.6 |
| Q2 FY2021 | Jun 30, 2021 | -348.8% | +176.5 |
| Q1 FY2021 | Mar 31, 2021 | -414.7% | +956.7 |
| Q4 FY2020 | Dec 31, 2020 | -210.1% | +827.6 |
| Q3 FY2020 | Sep 30, 2020 | -416.6% | +699.9 |
| Q2 FY2020 | Jun 30, 2020 | -525.3% | +329.7 |
| Q1 FY2020 | Mar 31, 2020 | -1371.5% | −594.6 |
| Q4 FY2019 | Dec 31, 2019 | -1037.8% | −29.9 |
| Q3 FY2019 | Sep 30, 2019 | -1116.5% | +510.4 |
| Q2 FY2019 | Jun 30, 2019 | -855.0% | +1054.0 |
| Q1 FY2019 | Mar 31, 2019 | -776.8% | +593.0 |
| Q4 FY2018 | Dec 31, 2018 | -1007.9% | +184.3 |
| Q3 FY2018 | Sep 30, 2018 | -1626.9% | −619.1 |
| Q2 FY2018 | Jun 30, 2018 | -1909.0% | −976.2 |
| Q1 FY2018 | Mar 31, 2018 | -1369.8% | −398.9 |
| Q4 FY2017 | Dec 31, 2017 | -1192.2% | −446.9 |
| Q3 FY2017 | Sep 30, 2017 | -1007.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -932.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -970.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -745.3% | – |
See a number that looks wrong?